IP37-16: Lesion-targeted MRI-guided transurethral ultrasound ablation for localized prostate cancer: 12-month safety, efficacy, and functional outcomes from a phase 2 trial

IP37-16: Lesion-targeted MRI-guided transurethral ultrasound ablation for localized prostate cancer: 12-month safety, efficacy, and functional outcomes from a phase 2 trial

Saturday, May 16, 2026 1:00 PM to 3:00 PM · 1 hr. 59 min. (America/New_York)
145AB
Abstract

Log in

See all the content and easy-to-use features by logging in or registering!